Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date of earliest event reported): November 12, 2007
HEMACARE
CORPORATION
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
California
|
000-15223
|
95-3280412
|
|
(State
or other jurisdiction
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
of
incorporation or organization)
|
|
|
|
|
|
15350
Sherman Way, Suite 350, Van Nuys, CA 91406
(Address
of principal executive offices) (Zip
Code)
(Registrant's
telephone number, including area code): 818-226-1968
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On
November 12, 2007, HemaCare Corporation (the “Company”) issued a press release
announcing financial results for the third quarter and the first nine months
of
2007 (the “Release”). A copy is attached as Exhibit 99.1 to this report and is
incorporated herein by reference.
Attached
to the Release is a table of condensed consolidated financial data. This table
inadvertently indicated that basic and diluted loss per share for the nine
months ended September 30, 2007 was $0.76 instead of the correct amount of
$0.74. In addition, this table inadvertently indicated that the basic and
diluted weighted average shares outstanding for the three months ended September
30, 2007 was 8,682,000 instead of the correct amount of 8,794,000. Finally,
this
table inadvertently indicated that basic and diluted weighted average shares
outstanding for the nine months ended September 30, 2007 was 8,357,000 instead
of the correct amount of 8,588,000. The information corrected in this Current
Report on Form 8-K will be accurately reported in the Company’s report on
Form 10-Q filed with the SEC.
The
information in this Current Report on Form 8-K, including the exhibits, will
not
be treated as "filed" for the purposes of Section 18 of the Securities and
Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section. This information will not be incorporated by
reference into a filing under the Securities Act of 1933, or into another filing
under the Exchange Act, unless that filing expressly refers to specific
information in this report.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
|
Exhibit
Number
|
Description
|
|
99.1
|
Press
release dated November 12, 2007
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Date:
|
November
14, 2007
|
HEMACARE
CORPORATION
By:
/s/
Robert S. Chilton
Robert
S. Chilton
Chief
Financial Officer
|
EXHIBIT
INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
Press
release dated November 12, 2007
|